NCT07204639 - Safety and Efficacy of RAP-103 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 22, 2025

Study Completion Date

December 30, 2025

Conditions

Psoriasis

Interventions

DRUG

RAP103 400mg single dose

RAP103 400mg single dose, orally 8 weeks

DRUG

RAP103 200mg BID

RAP103 200mg BID, orally 8 weeks

DRUG

Placebo for RAP400

Placebo for RAP400mg single dose for 8 weeks

DRUG

Placebo for RAP200mg

Placebo for RAP400mg single dose for 8 weeks

Trial Locations (1)

Innovacion y Desarrollo de Estrategias en Salud, Mexico City